|
Glioma
|
|
0.720 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
|
0.710 |
GeneticVariation
|
UNIPROT |
|
|
|
|
melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Melanomas from 10 separate patients (4.9%) were positive for IDH1 R132C (nine) or R132S (one).
|
30003571 |
2018 |
|
Hemangioma
|
|
0.020 |
GeneticVariation
|
BEFREE |
R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.
|
23485734 |
2013 |
|
Neoplasms, Vascular Tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.
|
23485734 |
2013 |
|
Congenital Abnormality
|
|
0.010 |
GeneticVariation
|
BEFREE |
R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.
|
23485734 |
2013 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
A majority of the tumors harbored an IDH1 mutation (p.R132H in 3 tumors; p.R132C in 4 tumors from 2 patients; p.R132L and p.R132G in one tumor each).
|
31240473 |
2019 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
A majority of the tumors harbored an IDH1 mutation (p.R132H in 3 tumors; p.R132C in 4 tumors from 2 patients; p.R132L and p.R132G in one tumor each).
|
31240473 |
2019 |
|
melanoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
A somatic, heterozygous IDH1 c.C394T (p.R132C) mutation was identified in one human melanoma metastasis to the lung.
|
20603105 |
2010 |
|
Secondary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
A somatic, heterozygous IDH1 c.C394T (p.R132C) mutation was identified in one human melanoma metastasis to the lung.
|
20603105 |
2010 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
Based on the overall analysis, 13 samples from 11 tumors had an R132H mutation and one tumor showed an R132G mutation.
|
23358936 |
2013 |
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
By screening dozens of reported natural compounds using both wild-type and mutant IDH1 enzymatic assays, we discovered Licochalcone A is a selective inhibitor to the R132C-mutant IDH1 with an IC<sub>50</sub> value of 5.176 μM, and inhibits the proliferation of sarcoma HT-1080 cells with an IC<sub>50</sub> value of 10.75 μM.
|
31836442 |
2020 |
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
By screening dozens of reported natural compounds using both wild-type and mutant IDH1 enzymatic assays, we discovered Licochalcone A is a selective inhibitor to the R132C-mutant IDH1 with an IC<sub>50</sub> value of 5.176 μM, and inhibits the proliferation of sarcoma HT-1080 cells with an IC<sub>50</sub> value of 10.75 μM.
|
31836442 |
2020 |
|
Astrocytoma
|
|
0.720 |
GeneticVariation
|
CLINVAR |
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
|
21352804 |
2011 |
|
Lymphoma, Non-Hodgkin
|
|
0.010 |
GeneticVariation
|
BEFREE |
Except for one non-Hodgkin lymphoma (NHL) patient harboring IDH1 mutation p.R132C, all IDH1 and IDH2 missense mutations were observed in patients with AML.
|
20946881 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Except for one non-Hodgkin lymphoma (NHL) patient harboring IDH1 mutation p.R132C, all IDH1 and IDH2 missense mutations were observed in patients with AML.
|
20946881 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Except for one non-Hodgkin lymphoma (NHL) patient harboring IDH1 mutation p.R132C, all IDH1 and IDH2 missense mutations were observed in patients with AML.
|
20946881 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Except for one non-Hodgkin lymphoma (NHL) patient harboring IDH1 mutation p.R132C, all IDH1 and IDH2 missense mutations were observed in patients with AML.
|
20946881 |
2010 |
|
Glioma
|
|
0.720 |
GeneticVariation
|
BEFREE |
For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1).
|
22396072 |
2012 |
|
Glioblastoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
|
Glioblastoma Multiforme
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
|
Childhood Glioblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
|
Adult Glioblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
|
Adult Fibrosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, using a genetically engineered inducible system, we report that selective suppression of endogenous mutant IDH1 expression in HT1080, a fibrosarcoma cell line with a native IDH1(R132C) heterozygous mutation, significantly inhibits cell proliferation and decreases clonogenic potential.
|
22885298 |
2012 |
|
Fibrosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, using a genetically engineered inducible system, we report that selective suppression of endogenous mutant IDH1 expression in HT1080, a fibrosarcoma cell line with a native IDH1(R132C) heterozygous mutation, significantly inhibits cell proliferation and decreases clonogenic potential.
|
22885298 |
2012 |